Cannara Biotech Past Earnings Performance
Past criteria checks 1/6
Cannara Biotech has been growing earnings at an average annual rate of 74.5%, while the Personal Products industry saw earnings growing at 3.7% annually. Revenues have been growing at an average rate of 59% per year. Cannara Biotech's return on equity is 6.5%, and it has net margins of 6.9%.
Key information
74.5%
Earnings growth rate
75.2%
EPS growth rate
| Personal Products Industry Growth | 8.7% |
| Revenue growth rate | 59.0% |
| Return on equity | 6.5% |
| Net Margin | 6.9% |
| Last Earnings Update | 31 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cannara Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 May 24 | 77 | 5 | 18 | 1 |
| 29 Feb 24 | 73 | 6 | 17 | 1 |
| 30 Nov 23 | 66 | 9 | 15 | 1 |
| 31 Aug 23 | 57 | 7 | 14 | 1 |
| 31 May 23 | 51 | 5 | 13 | 1 |
| 28 Feb 23 | 45 | 3 | 11 | 1 |
| 30 Nov 22 | 40 | 3 | 11 | 1 |
| 31 Aug 22 | 36 | 2 | 10 | 1 |
| 31 May 22 | 30 | 1 | 10 | 1 |
| 28 Feb 22 | 27 | 1 | 9 | 1 |
| 30 Nov 21 | 22 | 1 | 8 | 2 |
| 31 Aug 21 | 17 | -2 | 7 | 2 |
| 31 May 21 | 11 | -7 | 7 | 2 |
| 28 Feb 21 | 5 | -11 | 7 | 3 |
| 30 Nov 20 | 3 | -13 | 8 | 3 |
| 31 Aug 20 | 3 | -12 | 9 | 3 |
| 31 May 20 | 3 | -12 | 11 | 2 |
| 29 Feb 20 | 2 | -12 | 12 | 1 |
| 30 Nov 19 | 2 | -13 | 11 | 0 |
| 31 Aug 19 | 2 | -12 | 11 | 0 |
| 31 Aug 18 | 1 | -4 | 4 | 0 |
Quality Earnings: 8CB0 has a large one-off gain of CA$2.3M impacting its last 12 months of financial results to 31st May, 2024.
Growing Profit Margin: 8CB0's current net profit margins (6.9%) are lower than last year (9.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8CB0 has become profitable over the past 5 years, growing earnings by 74.5% per year.
Accelerating Growth: 8CB0's earnings growth over the past year (9.2%) is below its 5-year average (74.5% per year).
Earnings vs Industry: 8CB0 earnings growth over the past year (9.2%) did not outperform the Personal Products industry 16.5%.
Return on Equity
High ROE: 8CB0's Return on Equity (6.5%) is considered low.